TheraRadar
← Back
Data updated: Mar 29, 2026

LONG GROVE PHARMS

MetabolicOncologyCardiovascular
Pharma

LONG GROVE PHARMS is a pharmaceutical company focused on Metabolic, Oncology, Cardiovascular. Key products include NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE.

2008
Since
13
Drugs
-
Trials
128
Approved (2yr)

Key Drugs

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
norepinephrine bitartrate
alpha-adrenergic receptor 1 indications · 2022

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

ESTRADIOL 2026-02-02
METHADONE HYDROCHLORIDE 2026-01-22
Manufacturing (CMC)
ESTRADIOL 2026-01-22
Labeling
SODIUM BICARBONATE 2026-01-13
METHADONE HYDROCHLORIDE 2025-12-23
Labeling
METHADONE HYDROCHLORIDE 2025-12-23
Labeling
METHADONE HYDROCHLORIDE 2025-12-22
Labeling
METHADONE HYDROCHLORIDE 2025-12-22
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 40%
2 drugs
Oncology 40%
2 drugs
Cardiovascular 20%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Merck big-pharma
Oncology, Cardiovascular, Metabolic
Johnson & Johnson big-pharma
Oncology, Cardiovascular, Metabolic
Bayer big-pharma
Oncology, Cardiovascular, Metabolic
AstraZeneca big-pharma
Oncology, Cardiovascular, Metabolic
Boehringer Ingelheim big-pharma
Metabolic, Oncology, Cardiovascular